ArticleJournal of muscle research and cell motility2026
Amiodarone disrupts thyroid hormone homeostasis and impairs myogenic progression and locomotor function in zebrafish embryos.
Article in Journal of muscle research and cell motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Thyroid hormones (THs) are critical regulators of vertebrate embryonic development, governing cell proliferation, lineage commitment, and tissue maturation, including skeletal muscle formation. Disruption of TH homeostasis during early development can therefore have profound consequences for myogenesis and locomotor function. In this study, we investigated the effects of amiodarone, a known disruptor of TH metabolism, on muscle development and motility in zebrafish (Danio rerio) embryos. A dose-range analysis identified 0.01 mM amiodarone as a sublethal concentration suitable for mechanistic investigation, and LC-MS analysis confirmed compound uptake in embryos. Amiodarone exposure resulted in distinct developmental abnormalities, including craniofacial defects at 48 hpf and axial curvature and tail malformations by 72 hpf, accompanied by significantly reduced hatching success and bradycardia. Consistent with impaired neuromuscular function, treated larvae exhibited a markedly attenuated touch-evoked escape response with reduced swimming distance and velocity. Hormonal profiling revealed a significant reduction in triiodothyronine (T3) levels with a modest accumulation of thyroxine (T4), indicating disruption of TH homeostasis. At the molecular level, amiodarone altered the expression of Notch-associated regulators and key myogenic and cell-cycle genes, including downregulation of her6, her9, her12, hey2, sox9, and pcna, alongside upregulation of hey1, heyl, tp53, and casp3. These transcriptional changes were supported by reduced MYOD and PCNA protein levels and increased cleaved CASPASE-3, indicating impaired myogenic progression, reduced proliferation, and enhanced apoptosis. Collectively, these findings demonstrate that disruption of TH homeostasis by amiodarone compromises muscle development and locomotor function during zebrafish embryogenesis, underscoring the central role of endocrine regulation in early myogenic programs.
Indexed as
Identifiers
41865141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.